查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2141720

匹莫範色林藥物市場：全球市場預測，2026-2032年

Pimavanserin Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，匹馬鹼類藥物市場將成長至 28.7 億美元，複合年成長率為 8.44%。

主要市場統計數據
基準年 2025 16.3億美元
預計年份：2026年 17.4億美元
預測年份 2032 28.7億美元
複合年成長率 (%) 8.44%

匹莫凡色林製劑：概述

匹莫範色林是一種選擇性5-羥色胺2A受體反向促效劑，用於治療神經系統和精神疾病。其已確立的臨床應用是治療成人帕金森氏症精神病相關的幻覺和妄想。市場走向受多種因素影響，包括診斷意識、專科醫生處方、循證醫學要求、安全性監測、醫保覆蓋範圍以及對其他適應症的探索。由於治療決策涉及脆弱的患者群體和複雜的合併症，臨床差異化和負責任的藥物安全監測仍然是長期應用的關鍵。

臨床實務和法規如何改變匹馬巴貝林的使用

目前，帕金森氏症及相關疾病的治療重點正從單純的症狀控制轉向神經精神併發症的綜合管理。人們日益關注看護者負擔、生活品質、藥物依從性以及避免運動功能惡化等問題，這些問題正在影響治療方案的選擇。監管機構和相關人員繼續優先考慮隨機對照試驗的證據、有意義的患者結局、不利事件的特徵描述以及針對失智症相關精神病患者群體的清晰附加檔。專科醫生的可及性、診斷流程、預先核准以及各國處方框架的差異也會影響患者獲得該藥物的機會。

人工智慧對匹莫範色林藥物研發和治療的累積影響

人工智慧可以透過從臨床記錄中識別合格的患者、提高對幻覺和妄想的識別能力，以及協助進行治療反應和耐受性的長期監測，從而為匹莫範色林生態系統提供支援。在研究中，機器學習技術可用於受試者分層、識別具有臨床意義的亞組，以及整合影像學、遺傳學、症狀評定量表和真實世界數據（REW）。然而，這些應用需要謹慎的檢驗，因為資料偏差、診斷編碼不一致、隱私限制和模型不透明都可能導致不安全的建議。在人工智慧工具能夠影響處方和臨床試驗決策之前，人工臨床監督、透明的檢驗和前瞻性評估仍然至關重要。

區域性對匹馬巴塞林現況的見解

北美地區擁有完善的專科診療路徑，對帕金森氏症相關精神病症狀的應對也相對成熟，但保險公司的規定和安全方面的考量會影響患者的就醫。歐洲在運動障礙領域擁有高水準的專業知識，但其保險報銷和醫療技術評估流程因國家而異。亞太地區在診斷、專科醫生密度、監管實施以及創新療法的可及性方面存在顯著差異。拉丁美洲的特點是神經科醫生數量不均、公共和私人保險覆蓋範圍存在差異，以及對進口產品的依賴。中東地區既有資源豐富的三級醫療體系，也有專科資源匱乏的地區。非洲在診斷、藥物安全監測基礎設施以及神經系統藥物的可近性方面面臨巨大的差距，因此加強教育和醫療衛生體系建設尤為重要。

集團層級優先：東協、金磚國家、歐盟、七國集團、海灣合作理事會和北約

東協市場需要靈活的因應方式，充分考慮各成員國不同的監管體系、醫療財政狀況、專科醫師資源。金磚國家雖然擁有龐大且多元化的患者群體，但各國在藥品研發能力、核准流程和報銷體系方面存在差異。歐盟受益於監管協調，但在定價、評估和臨床應用方面仍存在差異。七國集團（G7）國家通常擁有強大的科研和專科基礎設施，但對實證醫學和安全性的要求也很高。海灣合作理事會（GCC）國家的醫療體系傾向於集中採購和先進的三級醫療服務，但醫療專業人員分佈仍然不均衡。北約成員國並非單一的醫療市場，但其重疊的公共衛生和科研網路可以促進在臨床標準、災害防備和資料管治的合作。

各國在取得和使用匹馬巴塞林方面的趨勢

在美國，專科醫師處方、保險公司保單和上市後安全評估是影響藥物使用的關鍵因素。在加拿大，省級報銷結構和專科轉診模式影響著藥物的可近性。在澳大利亞，全國性的法律規範和區域間運動障礙專科診療資源的差異是關鍵。在英國，實證審查、醫療系統授權和專科診療路徑備受重視。在法國、德國、義大利和西班牙，強大的臨床能力與獨特的報銷和處方流程相結合，並置於廣泛的歐洲框架內。日本和韓國擁有先進的醫療體系，但需要與當地的證據和監管要求相協調。在中國和印度，儘管神經系統疾病的診療能力正在不斷提升，但區域間的可近性差異仍然顯著。在巴西、墨西哥和俄羅斯，不同的公共、私人和專科醫療路徑，以及相關的法規和採購條件，都會影響藥物的可近性。在上述所有國家，準確的診斷、看護者的支持以及對治療相關不利事件的監測都至關重要。

匹莫凡色林發展與護理領導者指南

產業領導者應優先考慮針對明確界定的患者群體（包括對患者及其看護者至關重要的結局指標）的高品質證據。應加強對神經科醫生、精神科醫生、老年科醫生、基層醫療團隊和看護者的教育，內容涵蓋診斷、合理用藥、藥物交互作用和安全性監測。藥物取得策略應根據國家健保報銷體系量身定做，並以透明的衛生經濟學證據為支撐，而非基於宣傳性假設。健全的藥物安全性監測、私人真實世界數據和經獨立檢驗的數位化工具能夠提升研究的可信度。應與臨床醫生和患者團體合作，在確保知情同意和負責任的溝通的前提下，解決諸如診斷延遲、治療延遲、用藥依從性障礙和公平獲取藥物等挑戰。

關於匹莫凡色林的調查方法：執行摘要

本摘要基於對匹莫範色林製劑的市場範圍以及已公開的臨床、監管和醫療保健系統相關因素的系統性回顧。分析按治療實踐、創新、人工智慧、地區、國家組和單一國家/地區對研究結果進行分類。重點在於檢驗的定性證據，避免未經證實的數值聲明、市場估算和預測、市場佔有率以及公司特定聲明。隨著監管決策、臨床試驗結果、安全性資訊、報銷政策和治療指南的變化，應重新審視本摘要的解讀。

結論：在匹莫範色林治療中建立負責任的領導力

匹莫凡色林的作用在於緩解帕金森氏症相關的精神症狀。在此領域，平衡症狀緩解與安全性、運動功能、合併症以及看護者需求至關重要。未來的進展不僅取決於藥物的廣泛應用，還取決於準確的診斷、專科醫生與基層醫療醫生之間的協作、可靠的證據、公平的保險報銷以及嚴格的監測。考慮到地區和國家差異，本地化實施是必要的，但只有在確保檢驗、透明度和臨床課責之後，才能實施人工智慧（AI）應用。那些能夠平衡科學嚴謹性、以病人為中心的用藥途徑和藥物安全監測的領導者，最能有效地支持合理用藥。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：匹莫範色林藥物市場：依適應症分類

  • 與阿茲海默症相關的精神病
  • 與帕金森氏症相關的精神病
  • 思覺失調症

第8章：匹莫範色林藥物市場：依患者年齡層分類

  • 成人
  • 老年人

第9章：匹莫範色林藥物市場：依劑型分類

  • 17 Mg
  • 34 Mg

第10章：匹莫範色林藥品市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：匹莫範色林藥物市場：依最終用戶分類

  • 居家照護服務提供者
  • 醫院
  • 專科診所

第12章：匹莫範色林藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：匹莫範色林藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：匹莫範色林藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • ACADIA Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • Bajaj Healthcare Ltd.
  • Cipla Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Eris Lifesciences Ltd.
  • Global Pharma Tek Inc.
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Nhwa Pharmaceutical Co. Ltd.
  • LGM Pharma Inc.
  • Livzon Group Xinbeijiang Pharmaceutical Manufacturing Inc.
  • MSN Life Sciences Pvt. Ltd.
  • Olon SpA
  • Polpharma SA
  • Sun Pharmaceutical Industries Ltd.
  • Zentiva ks
  • Zhejiang Jingxin Pharmaceutical Co. Ltd.
  • Zydus Lifesciences Ltd.

第17章 主要專家

Product Code: MRR-9C4233EE5E4A

The Pimavanserin Drugs Market is projected to grow by USD 2.87 billion at a CAGR of 8.44% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.63 billion
Estimated Year [2026] USD 1.74 billion
Forecast Year [2032] USD 2.87 billion
CAGR (%) 8.44%

Pimavanserin Drugs: Executive Overview

Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist developed for neurologic and psychiatric indications. Its established clinical role is the treatment of hallucinations and delusions associated with Parkinson's disease psychosis in adults. The market's direction is shaped by diagnostic recognition, specialist prescribing, evidence requirements, safety monitoring, reimbursement access, and the pursuit of additional indications. Because treatment decisions involve vulnerable patients and complex comorbidities, clinical differentiation and responsible pharmacovigilance remain central to long-term adoption.

How Clinical Practice and Regulation Are Reshaping Pimavanserin Use

The landscape is shifting from symptom control alone toward integrated management of neuropsychiatric complications in Parkinson's disease and related disorders. Greater attention to caregiver burden, quality of life, medication adherence, and avoidance of motor-function deterioration is influencing treatment selection. Regulators and clinical stakeholders continue to emphasize randomized evidence, meaningful patient outcomes, adverse-event characterization, and clear labeling for populations with dementia-related psychosis. Access is also affected by specialist availability, diagnostic pathways, prior authorization, and differences in national prescribing frameworks.

Artificial Intelligence's Cumulative Impact on Pimavanserin Development and Care

Artificial intelligence can support the pimavanserin ecosystem by identifying eligible patients from clinical records, improving recognition of hallucinations and delusions, and assisting longitudinal monitoring of treatment response and tolerability. In research, machine-learning methods may help stratify participants, detect clinically relevant subgroups, and integrate imaging, genetics, symptom scales, and real-world evidence. These applications require careful validation because biased data, inconsistent diagnostic coding, privacy constraints, and opaque models can produce unsafe recommendations. Human clinical oversight, transparent validation, and prospective assessment remain essential before AI-supported tools influence prescribing or trial decisions.

Regional Insights Across the Pimavanserin Landscape

North America is characterized by established specialist care pathways and comparatively mature attention to Parkinson's disease psychosis, while payer controls and safety considerations influence access. Europe combines strong movement-disorder expertise with country-specific reimbursement and health-technology assessment processes. Asia-Pacific presents substantial diversity in diagnosis, specialist density, regulatory implementation, and access to innovative therapies. Latin America is shaped by uneven availability of neurologists, public and private coverage differences, and imported-product dependence. The Middle East shows variation between highly resourced tertiary systems and settings with limited specialist capacity. Africa faces pronounced gaps in diagnosis, pharmacovigilance infrastructure, and access to neurologic medicines, making education and health-system strengthening especially important.

Group-Level Priorities: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets require adaptable approaches that account for diverse regulatory systems, healthcare financing, and specialist access across member states. BRICS economies combine large and varied patient populations with differing domestic pharmaceutical capabilities, approval pathways, and reimbursement structures. The European Union benefits from regulatory coordination but retains national variation in pricing, assessment, and clinical implementation. G7 countries generally have stronger research and specialist infrastructure, alongside demanding evidence and safety expectations. GCC systems often emphasize centralized procurement and advanced tertiary care, while workforce distribution remains uneven. NATO members are not a single healthcare market, but their overlapping public-health and research networks can facilitate collaboration in clinical standards, preparedness, and data governance.

Country-Level Signals for Pimavanserin Access and Adoption

In the United States, specialist prescribing, payer policy, and post-market safety evaluation are important determinants of use. Canada's provincial reimbursement structures and specialist referral patterns shape availability. Australia combines national regulatory oversight with geographically uneven access to movement-disorder expertise. The United Kingdom emphasizes evidence review, health-system commissioning, and specialist pathways. France, Germany, Italy, and Spain each pair strong clinical capabilities with distinct reimbursement and prescribing processes within the broader European framework. Japan and South Korea have advanced healthcare systems but require alignment with local evidence and regulatory expectations. China and India show expanding neurologic-care capacity alongside substantial regional variation in access. Brazil, Mexico, and Russia reflect differing public, private, and specialist-care pathways, with regulatory and procurement conditions influencing availability. Across all listed countries, accurate diagnosis, caregiver support, and monitoring for treatment-emergent adverse events are foundational.

Actions for Leaders in Pimavanserin Development and Care

Industry leaders should prioritize high-quality evidence in clearly defined patient populations, including outcomes that matter to patients and caregivers. They should strengthen education for neurologists, psychiatrists, geriatricians, primary-care teams, and caregivers on diagnosis, appropriate use, interactions, and safety monitoring. Access strategies should be tailored to national reimbursement systems and supported by transparent health-economic evidence rather than promotional assumptions. Robust pharmacovigilance, privacy-preserving real-world data, and independently validated digital tools can improve confidence. Partnerships with clinicians and patient organizations should address underdiagnosis, treatment delays, adherence barriers, and equitable access while preserving informed consent and responsible communication.

Research Methodology for the Pimavanserin Executive Summary

This summary uses a structured review of the supplied market scope and publicly established clinical, regulatory, and health-system considerations relevant to pimavanserin drugs. The analysis organizes findings across therapeutic practice, innovation, artificial intelligence, regions, country groups, and individual countries. It emphasizes verifiable qualitative evidence and avoids unsupported numerical claims, market estimates, forecasts, market shares, and company-specific assertions. Interpretation should be refreshed as regulatory decisions, clinical-trial findings, safety communications, reimbursement policies, and treatment guidelines evolve.

Conclusion: Building Responsible Momentum in Pimavanserin Care

Pimavanserin's role is anchored in addressing psychosis associated with Parkinson's disease, an area where symptom relief must be balanced with safety, motor function, comorbidity, and caregiver needs. Future progress will depend less on broad availability alone than on accurate diagnosis, specialist and primary-care coordination, credible evidence, equitable reimbursement, and disciplined monitoring. Regional and country differences require locally appropriate implementation, while AI should be introduced only with validation, transparency, and clinical accountability. Leaders that combine scientific rigor with patient-centered access and pharmacovigilance will be best positioned to support responsible use.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pimavanserin Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Alzheimer Disease Psychosis
  • 7.3. Parkinson Disease Psychosis
  • 7.4. Schizophrenia

8. Pimavanserin Drugs Market, by Patient Age Group

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Elderly

9. Pimavanserin Drugs Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. 17 Mg
  • 9.3. 34 Mg

10. Pimavanserin Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Pimavanserin Drugs Market, by End User

  • 11.1. Introduction
  • 11.2. Homecare Agencies
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Pimavanserin Drugs Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Pimavanserin Drugs Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Pimavanserin Drugs Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. ACADIA Pharmaceuticals Inc.
  • 16.2. Aurobindo Pharma Ltd.
  • 16.3. Bajaj Healthcare Ltd.
  • 16.4. Cipla Ltd.
  • 16.5. Emcure Pharmaceuticals Ltd.
  • 16.6. Eris Lifesciences Ltd.
  • 16.7. Global Pharma Tek Inc.
  • 16.8. Intas Pharmaceuticals Ltd.
  • 16.9. Jiangsu Nhwa Pharmaceutical Co. Ltd.
  • 16.10. LGM Pharma Inc.
  • 16.11. Livzon Group Xinbeijiang Pharmaceutical Manufacturing Inc.
  • 16.12. MSN Life Sciences Pvt. Ltd.
  • 16.13. Olon S.p.A.
  • 16.14. Polpharma S.A.
  • 16.15. Sun Pharmaceutical Industries Ltd.
  • 16.16. Zentiva k.s.
  • 16.17. Zhejiang Jingxin Pharmaceutical Co. Ltd.
  • 16.18. Zydus Lifesciences Ltd.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Pimavanserin Drugs Market, Years Considered for the Study
  • FIGURE 2. Global Pimavanserin Drugs Market, Research Design
  • FIGURE 3. Global Pimavanserin Drugs Market, Research Framework
  • FIGURE 4. Global Pimavanserin Drugs Market, Data Triangulation
  • FIGURE 5. Global Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Pimavanserin Drugs Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global Pimavanserin Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Pimavanserin Drugs Market Size, by Patient Age Group, 2025 vs 2032 (%)
  • FIGURE 9. Global Pimavanserin Drugs Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Pimavanserin Drugs Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 11. Global Pimavanserin Drugs Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Pimavanserin Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global Pimavanserin Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Pimavanserin Drugs Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Pimavanserin Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Pimavanserin Drugs Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Pimavanserin Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Pimavanserin Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Pimavanserin Drugs Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Pimavanserin Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Pimavanserin Drugs Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Pimavanserin Drugs Market Segmentation & Coverage
  • TABLE 2. Global Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Alzheimer Disease Psychosis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Alzheimer Disease Psychosis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Alzheimer Disease Psychosis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Parkinson Disease Psychosis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Parkinson Disease Psychosis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Parkinson Disease Psychosis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Schizophrenia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Schizophrenia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Schizophrenia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 14. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Elderly Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Elderly Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Elderly Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 21. Global 17 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global 17 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global 17 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global 34 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global 34 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global 34 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 28. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 38. Global Homecare Agencies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Homecare Agencies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Homecare Agencies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Pimavanserin Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Asia-Pacific Pimavanserin Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Asia-Pacific Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 50. Asia-Pacific Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 51. Asia-Pacific Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 52. Asia-Pacific Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 53. Asia-Pacific Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 54. North America Pimavanserin Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. North America Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 56. North America Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 57. North America Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 58. North America Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 59. North America Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 60. Latin America Pimavanserin Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Latin America Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 62. Latin America Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 63. Latin America Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 64. Latin America Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 65. Latin America Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 66. Europe Pimavanserin Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Europe Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 68. Europe Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 69. Europe Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 70. Europe Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 71. Europe Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 72. Middle East Pimavanserin Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Middle East Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 74. Middle East Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 75. Middle East Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 76. Middle East Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 77. Middle East Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 78. Africa Pimavanserin Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Africa Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 80. Africa Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 81. Africa Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 82. Africa Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 83. Africa Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 84. Global Pimavanserin Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. ASEAN Pimavanserin Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. ASEAN Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 87. ASEAN Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 88. ASEAN Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 89. ASEAN Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 90. ASEAN Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 91. GCC Pimavanserin Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. GCC Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 93. GCC Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 94. GCC Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 95. GCC Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 96. GCC Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 97. European Union Pimavanserin Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. European Union Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 99. European Union Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 100. European Union Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 101. European Union Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 102. European Union Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 103. BRICS Pimavanserin Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. BRICS Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 105. BRICS Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 106. BRICS Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 107. BRICS Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 108. BRICS Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 109. G7 Pimavanserin Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 110. G7 Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 111. G7 Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 112. G7 Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 113. G7 Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 114. G7 Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 115. NATO Pimavanserin Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. NATO Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 117. NATO Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 118. NATO Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 119. NATO Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 120. NATO Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 121. Global Pimavanserin Drugs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 122. United States Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 123. United States Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 124. United States Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 125. United States Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 126. United States Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 127. United States Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 128. Canada Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 129. Canada Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 130. Canada Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 131. Canada Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 132. Canada Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 133. Canada Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 134. Mexico Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 135. Mexico Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 136. Mexico Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 137. Mexico Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 138. Mexico Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 139. Mexico Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 140. Brazil Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 141. Brazil Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 142. Brazil Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 143. Brazil Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 144. Brazil Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 145. Brazil Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 146. United Kingdom Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 147. United Kingdom Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 148. United Kingdom Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 149. United Kingdom Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 150. United Kingdom Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 151. United Kingdom Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 152. Germany Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 153. Germany Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 154. Germany Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 155. Germany Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 156. Germany Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 157. Germany Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 158. France Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 159. France Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 160. France Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 161. France Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 162. France Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 163. France Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 164. Russia Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 165. Russia Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 166. Russia Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 167. Russia Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 168. Russia Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 169. Russia Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 170. Italy Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 171. Italy Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 172. Italy Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 173. Italy Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 174. Italy Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 175. Italy Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 176. Spain Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 177. Spain Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 178. Spain Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 179. Spain Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 180. Spain Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 181. Spain Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 182. China Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 183. China Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 184. China Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 185. China Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 186. China Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 187. China Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 188. India Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 189. India Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 190. India Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 191. India Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 192. India Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 193. India Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 194. Japan Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 195. Japan Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 196. Japan Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 197. Japan Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 198. Japan Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 199. Japan Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 200. Australia Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 201. Australia Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 202. Australia Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 203. Australia Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 204. Australia Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 205. Australia Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 206. South Korea Pimavanserin Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 207. South Korea Pimavanserin Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 208. South Korea Pimavanserin Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 209. South Korea Pimavanserin Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 210. South Korea Pimavanserin Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 211. South Korea Pimavanserin Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 212. Global Pimavanserin Drugs Market Share, by Key Player, 2025
  • TABLE 213. Global Pimavanserin Drugs Market, Key Experts